CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 145 enrolled
Drug / intervention
MVA-NP+M1 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03883113
NCT03883113Phase 2Completed
CompareCT.gov

Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model

Barinthus Biotherapeutics·interventional·Posted Mar 20, 2019·Updated Mar 18, 2021

In Brief

A Phase 2 clinical trial evaluating MVA-NP+M1, Saline, and 1 other intervention for Influenza. Completed, enrolled 145 participants across 1 site.

Detailed Summary

A Phase 2, single center, randomized, double blind study evaluating the safety, efficacy, and immunogenicity of MVA NP+M1 in the H3N2 human influenza challenge model; on healthy adult volunteers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesBelgium
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedMar 20, 2019
Enrollment StartJun 3, 2019
Primary CompletionDec 16, 2019
Study CompletionApr 17, 2020
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 7.3 years ago

Interventions

MVA-NP+M1biological

Trial Vaccine

Salinebiological

Sodium Chloride Placebo

H3N2 (A/Belgium/2417/2015)biological

Challenge Agent